Dear All, Since April, UltraGreen.ai (ULG.SI) has seen its share price drop 19% from an intraday high of US$1.54 on April 27 to an intraday low of US$1.25 on May 18. More notably, despite the announcement of regulatory approval for Verdi in Singapore, the stock has fallen nearly 16% since the 1QFY26 business update. This naturally raises an important question for investors: Has the market overreacted, or has ULG’s growth story weakened materially? In my view, the latest quarter still supports the broader investment thesis that ULG remains an attractive long-term health care growth story, supported by recurring consumable revenues, strong margins and growing global acceptance of fluorescence-guided surgery (“FGS”) technologies. 1QFY26 Highlights and Investment Pros Before going into depth, readers can check out my previous LinkedIn post Here For a quick overview of ULG’s business areas. investment properties A) Broad-based volume growth across all geographies 1QFY26 shipment volumes improved sequentially in both…
